Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPANOVA vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
As an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/d L)
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
4 g orally once daily as 4 capsules of 1 g each with food.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Epanova (omega-3-carboxylic acids) is hydrolyzed by pancreatic lipase; free fatty acids are absorbed and then metabolized via beta-oxidation similarly to dietary fatty acids.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Highly protein bound (>99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Volume of distribution approximately 0.2 L/kg, indicating limited extravascular distribution.
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Intramuscular: ~100% (absolute bioavailability not determined in humans due to lack of IV formulation; presumed complete absorption from IM site).
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
No dose adjustment required for renal impairment, including end-stage renal disease on dialysis.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Safety and efficacy not established in pediatric patients under 18 years; no recommended dosing.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
No specific dose adjustment recommended; use with caution due to increased risk of adverse effects and comorbidities. Monitor hepatic function closely.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
None
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
May increase LDL-C levels; monitor LDL-C during therapy.,May prolong bleeding time; use with caution in patients receiving anticoagulants or with bleeding disorders.,Risk of atrial fibrillation or flutter in patients with prior cardiovascular disease or diabetes; discontinue if symptoms occur.
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to Epanova or any of its components.
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
Epanova may be taken with or without food, but taking with a low-fat meal may improve absorption. Avoid high-fat meals as they can increase GI side effects. Grapefruit juice has no known interaction. No significant food restrictions; maintain a heart-healthy diet.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the human dose (based on body surface area) did not reveal evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Excretion into human milk unknown. M/P ratio not available. Caution should be exercised when administered to a nursing mother. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
No specific dosing adjustments are recommended during pregnancy based on pharmacokinetic changes. The pharmacokinetics of icosapent ethyl have not been studied in pregnant women. Dose should be individualized based on triglyceride levels and tolerability.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
For patients with severe hypertriglyceridemia (≥500 mg/d L), Epanova (omega-3 carboxylic acids) reduces triglyceride levels by approximately 25-45% at doses of 2-4 g/day. Absorption is enhanced when taken with a low-fat meal; however, if meals cause GI distress, taking with food is still recommended. Avoid use in patients with known fish allergy. Monitor for atrial fibrillation or flutter, especially in elderly patients or those with cardiovascular risk factors. Dose should be adjusted for renal impairment (e GFR <30 m L/min).
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
Take Epanova exactly as prescribed, typically 2-4 capsules once daily with food to reduce GI side effects.,Do not break, crush, or chew the capsules; swallow them whole.,Continue a low-fat diet and exercise program while on this medication.,Inform your doctor if you experience symptoms of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Report any irregular heartbeat, chest pain, or shortness of breath immediately.,This medication may increase bleeding risk; tell your doctor if you have a bleeding disorder or take blood thinners (e.g., warfarin).,Store at room temperature away from moisture and heat.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPANOVA vs AMINO ACIDS, answered by our medical review team.
EPANOVA is a Parenteral Nutrition Solution that works by Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPANOVA and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPANOVA is: 4 g orally once daily as 4 capsules of 1 g each with food.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPANOVA and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPANOVA is classified as Category C. Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the huma. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.